Physician profile
Nidal Rahal
NPI 1235106154
$4,256.00
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $736 · 2021: $204 · 2022: $1,056 · 2023: $1,256 · 2024: $73.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $611.56 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $510.70 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $386.17 | 2019-2023 | Farxiga, Breztri, Evusheld |
| Merck Sharp & Dohme LLC | $261.19 | 2019-2023 | Dificid |
| Amgen INC. | $259.23 | 2019-2023 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $235.22 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $221.90 | 2019-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $193.28 | 2019-2024 | |
| Abbott Laboratories | $168.88 | 2020-2023 | Freestyle Libre 3, Infinity, Eterna |
| Astellas Pharma US INC | $150.68 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $143.35 | 2019-2022 | |
| Boston Scientific Corporation | $124.72 | 2022 | |
| Abbvie INC. | $109.59 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.95 | 2019-2020 | |
| Sk Life Science, INC. | $93.64 | 2023 | Xcopri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $90.78 | 2022 | |
| Sunovion Pharmaceuticals INC. | $82.95 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $82.11 | 2023 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $80.85 | 2023 | Rexulti |
| Dexcom, INC. | $52.22 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $40.16 | 2019-2020 | |
| Amarin Pharma, INC. | $39.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.23 | 2019 | |
| Corium, LLC | $36.89 | 2023 | Adlarity |
| Lundbeck LLC | $22.38 | 2023 | Rexulti |
| Ekos Corporation | $21.29 | 2019 | |
| Eisai INC. | $17.10 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.08 | 2023 | Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.47 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.40 | 2023 | Quviviq |
| Evoke Pharma, INC. | $13.28 | 2023 | Gimoti |
| Vyera Pharmaceuticals, LLC | $11.85 | 2019 | |
| Biogen, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidal Rahal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.